- Home
- / MEDIPOST
MEDIPOST
Stock Price
₩6.7 K
2024-10-29
Market Capitalization
₩226.8 B
2024-10-29
Revenue
₩70.7 B
FY, 2024
MEDIPOST Summary
Company Summary
- Overview
- MEDIPOST is a company active in the stem cell therapeutics and regenerative medicine fields. It offers an allogeneic human Umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) product named CARTISTEM for patients with knee osteoarthritis. The company also develops preventive treatment for bronchopulmonary dysplasia (BPD) and Alzheimer’s disease. In addition, MEDIPOST operates an umbilical cord blood bank.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Seongnam-si, KR | view all locations
- Website
- https://en.medi-post.co.kr/
- Cybersecurity rating
- ESG rating
Table of Contents
LocationsView all
2 locations detected
Seongnam-si, Gyeonggi-do HQ
Korea (Republic of)
644, 21 Daewangpangyo-ro, Bundang-gu
Seoul
Korea (Republic of)
306 Digital-ro, Guro-dong, Guro-gu
MEDIPOST Financials
Summary Financials
- Revenue (Q3, 2025)
- ₩55.7B
- Gross profit (Q3, 2025)
- ₩37.6B
- Net income (Q3, 2025)
- (₩58.0B)
- Cash (Q3, 2025)
- ₩35.0B
- EBIT (Q3, 2025)
- (₩65.2B)
- Enterprise value
- $203.5B
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026